ReviewFrontiers in pharmacology2020
Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Efficacy of tocilizumab in the treatment of COVID-19: An umbrella review.Reviews in medical virology · 2022Pooled it
- Interleukins in COVID-19 and SARS-CoV-2 Variants: Immunopathogenesis, Therapeutic Perspectives and Vaccine-Induced Immune Responses.International journal of molecular sciences · 2026Review
- Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.Journal of clinical medicine · 2025Review
- Immune Signatures Distinguish Pure and Mixed Sepsis in Critical COVID-19: A Retrospective Cohort Study.Journal of inflammation research · 2025Article
- Identification of key modules and hub genes for sepsis-induced myopathy using weighted gene co-expression network analysis.Frontiers in genetics · 2025Article
- The Role of Inflammation in the Pathogenesis of Viral Respiratory Infections.Microorganisms · 2024Review
- Using a static magnetic field to attenuate the severity in COVID-19-invaded lungs.Scientific reports · 2024Article
- Article
- A Bird's-Eye View of the Pathophysiologic Role of the Human Urobiota in Health and Disease: Can We Modulate It?Pathophysiology : the official journal of the International Society for Pathophysiology · 2024Review
- A Prospective Cohort Study of COVID-19: Evaluation of the Early Role of IL-1 and IL-6 Antagonists in Improving the Outcome of the Illness and Reduction in the Risk of Death.Healthcare (Basel, Switzerland) · 2023Article
- The optimal anticoagulation strategy for COVID-19, prophylactic or therapeutic?: a meta-analysis, trial sequential analysis, and meta-regression of more than 27,000 participants.Emergency and critical care medicine · 2022Article
- Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations.Infectious disease reports · 2022Review
- An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).International immunopharmacology · 2022Review
- Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.Frontiers in immunology · 2022Review
- An outlook on antigen-specific adoptive immunotherapy for viral infections with a focus on COVID-19.Cellular immunology · 2021Review
- Immune mediating molecules and pathogenesis of COVID-19-associated neurological disease.Microbial pathogenesis · 2021Review
- New perspective towards therapeutic regimen against SARS-CoV-2 infection.Journal of infection and public health · 2021Review
- COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies.Journal for immunotherapy of cancer · 2021Review
- Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.